Evidence Hub

Fluoroquinolone resistance in Streptococcus pyogenes

Richter SS, Diekema DJ, Heilmann KP, Almer LS, Shortridge VD, Zeitler R, Flamm RK, Doern GV

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003

Abstract

Streptococcus pyogenes isolated from blood and urine samples obtained from a 78-year-old woman was tested for susceptibility, and fluoroquinolone resistance (minimum inhibitory concentration of levofloxacin, 16 microg/mL) was found. DNA amplification and sequencing revealed a serine81-->tyrosine substitution in gyrA and 2 substitutions in parC: serine79-->phenylalanine and alanine121-->valine. This is the second report of a clinical isolate of S. pyogenes with high-level fluoroquinolone resistance.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free